<DOC>
	<DOCNO>NCT02363335</DOCNO>
	<brief_summary>Background : The drug Roflumilast ( Daliresp ) use treat Chronic Obstructive Pulmonary Disease ( COPD ) . COPD lung disease make difficult breathe . Studies show drug decrease blood sugar people type 2 diabetes . Sitagliptin ( Januvia ) medication presently use treat diabetes . Researchers think drug may decrease blood sugar cause increase hormone GLP-1.This hormone secrete small intestine stomach also know incretin . Researchers want study drug affect blood sugar , insulin , hormone blood . Objectives : - To study effect Roflumilast ( Daliresp ) Sitagliptin ( Januvia ) blood sugar insulin . - To good understand GLP-1 gut hormone . This may lead new treatment type 2 diabetes . Eligibility : - Healthy volunteer age 21 55 . - Body Mass Index ( BMI ) less 30 Design : -This study require one screen visit four study visit , schedule 3-weeks apart . Screening visit require participant arrive fast 10 hour follow : - Medical history , physical exam , height , weight , blood pressure measurement blood urine test . - A 2-hour oral glucose tolerance test ( OGTT ) . Participants drink orange-flavored drink contain 75 gram sugar ( 300 calorie ) . A blood sample take prior drinking beverage 2-hours later . - An electrocardiogram ( EKG ) measure electrical activity heart . - Questionnaires risk depression suicide . Study visit 1to 4 : - Participants arrive even prior blood work do confirm eligibility . They eat drink anything except water start 8:00 p.m. - About 6:30 a.m. follow day , I.V . ( small plastic tube ) place arm vein use take 20 blood sample period 11 hour . - Participants receive one follow study medication/placebo grouping random order : 1 . Roflumilast ( Daliresp ) 500 mcg pill ; 1 placebo pill 2 . Sitaglipitin ( Januvia ) 100 mg pill ; 1 placebo pill 3 . Roflumilast ( Daliresp ) 500 mcg pill ; Sitagliptin ( Januvia ) 100 mg pill 4 . 2 placebo pill - One hour later , 10-hour mixed meal test ( MMT ) . They ask drink nutritional shake ( Ensure Plus ) . Blood sample take next 10 hour measure blood sugar , insulin hormone . At end test , give meal . - Participants answer question side effect symptom . They receive follow-up phone call within 10 day .</brief_summary>
	<brief_title>The Role Phosphodiesterase Inhibitors Incretin Secretion</brief_title>
	<detailed_description>Objectives Specific Aims : We plan investigate whether phosphodiesterases involve regulation glucagon-like peptide-1 ( GLP-1 ) secretion L cell human . We hypothesize : ( 1 ) phosphodiesterase-4D ( PDE4D ) inhibitor ( roflumilast ) enhance GLP-1 secretion L cell ; ( 2 ) PDE4D inhibitor ( roflumilast ) DPP4 inhibitor ( sitagliptin ) synergistic effect increase amount circulate active GLP-1 . Experimental Design Methods : Twenty healthy adult , age 21-55 , recruit study . This randomized , double-blind , placebo-controlled cross-over study . Each subject serve his/her control person four different study visit space 3 week apart . During visit , receive one follow medication ( oral route ) random order : 1 . Roflumilast ( Daliresp ) 500 mcg + Placebo 2 . Sitagliptin ( Januvia ) 100 mg + Placebo 3 . Roflumilast ( Daliresp ) 500 mcg + Sitagliptin ( Januvia ) 100 mg 4 . Placebo A 10-hr mixed-meal test administer 1 hour medication frequent blood-samplings do 10 hour . Medical Relevance Expected Outcome : Preliminary clinical data show phosphodiesterase inhibitor improve glycemic control type 2 diabetes , pre-clinical animal data show phosphodiesterase inhibitor enhance GLP-1 secretion L cell . The application novel , pre-clinical finding understand human biology pathobiology fundamental critical importance . This study give u good understand regulator GLP-1 secretion human , new understanding may lead new treatment type 2 diabetes .</detailed_description>
	<mesh_term>Phosphodiesterase Inhibitors</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age 2155 ( Age restriction use remove age confound factor ( beta ) cell function insulin resistance tend deteriorate age may affect GLP1 GIP level . 2 . Screening laboratory evaluation clinically significant abnormal result ( minor deviation normal lab result discretion principal investigator ) : 1. fast comprehensive metabolic panel 2. complete blood count differential platelet 3. thyroid function test ( TSH ) 4. urine drug screen 5 . Point care urine pregnancy test ( woman surgically sterile ) 3 . BMI &lt; 30 ( participant BMI great equal 30 exclude obesity associate attenuation GLP1 secretion . 4 . Have history stable weight ( maintain weight within +/ 5 % ) past year 5 . Have NOT participate another clinical trial involve pharmacologic agent within past 30 day 6 . Able complete inform consent 7 . Agree participate clinical trial within study period ( discretion study investigator ) EXCLUSION CRITERIA : 1 . FPG great equal 100 mg/dl 2hr OGTT great equal 140 mg/dL ( evidence glucose intolerance diabetes ) 2 . History anemia , Hemoglobin &lt; 12.5 mg/dL men &lt; 11.5 mg/dL woman screen visit 3 . Weight &lt; 110 pound ( due blood volume requirement ) 4 . Evidence illicit drug use 5 . History substance abuse include marijuana within past 6 month 6 . History smoke tobacco product within six month prior screen 7 . Alcohol intake &gt; 30 gram ( drink 2 beer per day OR equivalent amount alcohol ) 8 . History Human Immunodeficiency Virus ( HIV ) infection 9 . History active chronic Hepatitis B and/or C infection 10 . History psychiatric illness include major depressive disorder , schizophrenia , bipolar disorder 11 . Any lifetime history suicide attempt 12 . History suicidal ideation type 4 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) last year 13 . Any suicidal ideation type 4 5 CSSRS followup visit . 14 . Patient Health Questionnaire9 ( PHQ9 ) score great equal 10 screen visit followup study visit 15 . Generalized Anxiety Disorder7 ( GAD7 ) score great equal 10 screen visit followup visit 16 . History pancreatitis 17 . History liver renal disease 18 . History gastrointestinal endocrine disorder 19 . History malignancy ( unless P.I . determines impact prior malignancy study outcome , i.e . basal cell skin cancer ) 20 . History coronary disease clinically significant abnormality electrocardiogram 21 . History seizures neurologic disease 22 . History glucocorticoid use ( one month ) immunosuppressive agent ( ) , i.e . Imuran , Neoral , Sandimmune , SangCya , basiliximab ( Simulect ) , daclizumab ( Zenapax ) , muromonab ( Orthocolone OKT ( 3 ) ) prednisone ( Deltasone , Orasone ) within past six month 23 . Use proton pump inhibitor ( PPI ) , i.e . Prilosec , Prevacid , Achiphex , Protonix , Nexium , Zegarid 24 . Women pregnant nursing/breastfeeding child 25 . Any medical history , opinion investigator ( ) , may make participation subject study unsafe</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 19, 2016</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>Phosphodiesterase Inhibitor</keyword>
	<keyword>GLP</keyword>
</DOC>